Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factor VIII inhibitors: a clinical overview.

G C White, C W McMillan, P M Blatt

    American Journal of Hematology
    |December 1, 1982
    PubMed
    Summary

    Inhibitors in hemophilia result from an immune response to Factor VIII (FVIII) material. Genetic factors and FVIII levels influence inhibitor development and clinical presentation.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A Case of Functional, Simulating Organic Disease of the Heart.

    Western journal of medicine and surgery·2024
    Same author

    Immune tolerance induction: What have we learned over time?

    Haemophilia : the official journal of the World Federation of Hemophilia·2018
    Same author

    Harold Ross Roberts, M.D: inspirational mentor, consummate physician, superb scientist (1930-2017).

    Journal of thrombosis and haemostasis : JTH·2017
    Same author

    Future developments in the treatment of haemophilia B.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016
    Same author

    Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016
    Same author

    A multicenter study of recombinant factor VIII (Recombinate(TM) ) in previously treated patients with hemophilia A.

    Haemophilia : the official journal of the World Federation of Hemophilia·2016

    Area of Science:

    • Immunology
    • Hematology
    • Genetics

    Background:

    • Classical hemophilia involves a deficiency in Factor VIII (FVIII).
    • Patients with hemophilia can develop inhibitors, which are antibodies against FVIII.
    • These inhibitors complicate treatment by neutralizing FVIII activity.

    Purpose of the Study:

    • To explore the immunological basis of Factor VIII inhibitors in hemophilia.
    • To identify factors influencing inhibitor development and characteristics.
    • To review current therapeutic approaches for bleeding episodes in inhibitor patients.

    Main Methods:

    • Review of existing evidence on inhibitor formation.
    • Immunochemical analysis of inhibitor composition (gamma G3/G4 heavy chains).
    • Analysis of patient factors: genetics, basal FVIII levels, and exposure to FVIII material.

    Main Results:

    • Inhibitors arise from an immunological response to FVIII (VIII:C or VIII:CAg) exposure.
    • Inhibitors are typically antibodies with specific heavy chain compositions (gamma G3/G4).
    • Exposure to FVIII triggers an anamnestic response, increasing inhibitor levels.

    Conclusions:

    • Inhibitor development is influenced by genetic factors, FVIII levels, and immunizing material.
    • Therapeutic strategies primarily focus on managing acute bleeding.
    • Understanding the immunobiology of inhibitors is crucial for future treatment advancements.

    Related Experiment Videos